Randomized phase III study (SPEAR) of picoplatin plus best supportive care (BSC) or BSC alone in patients (pts) with SCLC refractory or progressive within 6 months after first-line platinum-based chemotherapy.

被引：26
|
作者：
Ciuleanu, T.
Samarzjia, M.
Demidchik, Y.
Beliakouski, V.
Rancic, M.
Bentsion, D. L.
Orlov, S. V.
Schaeffier, B. A.
De Jager, R. L.
Breitz, H. B.
机构：
[1] Inst Oncol I Chiricuta, Cluj Napoca, Romania
[2] Clin Pulm Dis, Zagreb, Croatia
[3] Minsk City Clin Oncol Dispensary, Minsk, BELARUS
[4] Gomel Reg Oncol Dispensary, Gomel, BELARUS
[5] Clin Ctr Nis, Nish, Serbia
[6] Sverdiovsk Reg Oncol Ctr, Ekaterinburg, Russia
[7] St Petersburg Pavlov State Med Univ, St Petersburg, Russia
[8] Poniard Pharmaceut Inc, San Francisco, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.7002
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7002
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Maintenance avelumab plus best supportive care (BSC) versus BSC alone after platinum-based first-line (1L) chemotherapy in advanced urothelial carcinoma (UC): JAVELIN Bladder 100 phase III interim analysis.
    Powles, Thomas
    Park, Se Hoon
    Voog, Eric
    Caserta, Claudia
    Valderrama, B. P.
    Gurney, Howard
    Kalofonos, Haralabos
    Radulovic, Sinisa
    Demey, Wim
    Ullen, Anders
    Loriot, Yohann
    Sridhar, Srikala S.
    Tsuchiya, Norihiko
    Kopyltsov, Evgeny
    Sternberg, Cora N.
    Bellmunt, Joaquim
    Aragon-Ching, Jeanny B.
    Petrylak, Daniel Peter
    di Pietro, Alessandra
    Grivas, Petros
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (18)
  • [2] A multicentre, international, randomised, open-label phase 3 trial of avelumab plus best supportive care (BSC) vs BSC alone as maintenance therapy after first-line platinum-based chemotherapy in patients with advanced urothelial cancer (JAVELIN bladder 100)
    Powles, T.
    Grivas, P.
    Aragon-Ching, J. B.
    Faroun, Y.
    Kessler, E. R.
    Tomita, Y.
    Chakrabarti, D.
    Laliberte, R. J.
    Shnaidman, M.
    Petrylak, D.
    ANNALS OF ONCOLOGY, 2016, 27
  • [3] Randomized phase II study of niraparib plus best supportive care (BSC) versus BSC alone as maintenance treatment in patients with advanced urothelial carcinoma (UC) whose disease did not progress after first-line platinum-based chemotherapy (PBCT): The Meet-URO12 trial.
    Vignani, Francesca
    Tambaro, Rosa
    De Giorgi, Ugo
    Giannatempo, Patrizia
    Bimbatti, Davide
    Carella, Claudia
    Stellato, Marco
    Atzori, Francesco
    Aieta, Michele
    Masini, Cristina
    Hamzaj, Alketa
    Ermacora, Paola
    Veccia, Antonello
    Pignata, Sandro
    Lolli, Cristian
    Procopio, Giuseppe
    Pierantoni, Francesco
    Zonno, Antonia
    Santini, Daniele
    Di Maio, Massimo
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [4] A multicenter, randomized phase III trial comparing second-line chemotherapy (SLC) plus best supportive care (BSC) with BSC alone for pretreated advanced gastric cancer (AGC)
    Park, S. H.
    Lim, D. H.
    Park, K.
    Lee, S.
    Oh, S. Y.
    Kwon, H.
    Kang, J. H.
    Hwang, I. G.
    Lee, J.
    Park, J. O.
    Park, Y. S.
    Lim, H. Y.
    Kang, W. K.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [5] A randomized phase III trial comparing sorafenib plus best supportive care (BSC) versus BSC alone in Child-Pugh B patients (pts) with advanced hepatocellular carcinoma (HCC): The BOOST study
    Daniele, Bruno
    Di Maio, Massimo
    Gallo, Ciro
    Gasbarrini, Antonio
    Carteni, Giacomo
    Di Costanzo, Giovan Giuseppe
    Craxi, Antonio
    Cabibbo, Giuseppe
    Bolondi, Luigi
    Granito, Alessandro
    Missale, Gabriele
    Frassoldati, Antonio
    Angelico, Mario
    Roselli, Mario
    Daniele, Gennaro
    Perrone, Francesco
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [6] CCTG CO.26 trial: A phase II randomized study of durvalumab (D) plus tremelimumab (T) and best supportive care (BSC) versus BSC alone in patients (pts) with advanced refractory colorectal carcinoma (rCRC).
    Chen, Eric Xueyu
    Jonker, Derek J.
    Kennecke, Hagen F.
    Berry, Scott R.
    Couture, Felix
    Ahmad, Chaudhary E.
    Goffin, John R.
    Kavan, Petr
    Harb, Mohammed
    Colwell, Bruce
    Samimi, Setareh
    Samson, Benoit
    Abbas, Tahir
    Aucoin, Nathalie
    Aubin, Francine
    Koski, Sheryl L.
    Wei, Alice Chia-chi
    Magoski, Nadine M.
    Tu, Dongsheng
    O'Callaghan, Christopher J.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [7] CASPIAN: Phase 3 Study of First-Line Durvalumab ± Tremelimumab plus Platinum-Based Chemotherapy vs Chemotherapy Alone in ED-SCLC
    Paz-Ares, L.
    Jiang, H.
    Huang, Y.
    Dennis, P.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2398 - S2398
  • [8] Nintedanib plus best supportive care (BSC) versus placebo plus BSC for the treatment of patients (pts) with colorectal cancer (CRC) refractory to standard therapies: Results of the phase III LUME-colon 1 study
    Van Cutsem, E.
    Yoshino, T.
    Lenz, H-J.
    Lonardi, S.
    Falcone, A.
    Limon, M. L.
    Saunders, M. P.
    Sobrero, A.
    Maiello, E.
    Park, Y. S.
    Ferreiro Monteagudo, R.
    Hong, Y. S.
    Tomasek, J.
    Taniguchi, H.
    Ciardiello, F.
    Hocke, J.
    Oum'hamed, Z.
    Vlassak, S.
    Studeny, M.
    Tabernero, J.
    ANNALS OF ONCOLOGY, 2016, 27
  • [9] A Multicenter, Randomized, Double-blind, Phase II Study of TAS-102 (A) Plus Best Supportive Care (BSC) Versus Placebo (P) Plus BSC in Patients (pts) With Chemotherapy-refractory Metastatic Colorectal Cancer (mCRC)
    Kuboki, Y.
    Yoshino, T.
    Yamazaki, K.
    Nishina, T.
    Komatsu, Y.
    Baba, H.
    Tsuji, A.
    Yamaguchi, K.
    Muro, K.
    Ohtsu, A.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S392 - S392
  • [10] Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy
    Bellmunt, J.
    Fougeray, R.
    Rosenberg, J. E.
    von der Maase, H.
    Schutz, F. A.
    Salhi, Y.
    Culine, S.
    Choueiri, T. K.
    ANNALS OF ONCOLOGY, 2013, 24 (06) : 1466 - 1472
12345